Imara, Inc.   Report issue

For profit Phase 2
Founded: Cambridge MA United States (2016)
Status: Acquired by Enliven Therapeutics (2022)

Organization Overview

First Clinical Trial
2016
NCT02998450
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Imara, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

Tovinontrine (6 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia, Sickle Cell (Phase 2)

beta-Thalassemia (Phase 2)

Hemoglobin SC Disease (Phase 1)

Thalassemia (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 1